

## Press Release

### **Astellas Announces Personnel Changes**

**TOKYO, October 24, 2019** - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas” ) today announced that the personnel changes as below.

1. Change in the responsibility of Corporate Officer      Effective October 25, 2019

Naoki Okamura

(New)      Representative Director, Corporate Executive Vice President,  
Chief Strategy Officer (CStO) and Chief Financial Officer (CFO)

(Current)      Representative Director, Corporate Executive Vice President,  
Chief Strategy Officer (CStO)

2. Resignation of Senior Corporate Executive      Effective October 24, 2019

Chikashi Takeda

(Current)      Senior Corporate Executive, Chief Financial Officer (CFO)

**About Astellas**

Astellas Pharma Inc., based in Tokyo, Japan, is a company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceutical products. For more information, please visit our website at <https://www.astellas.com/en>

**Cautionary Notes**

In this press release, statements made with respect to current plans, estimates, strategies and beliefs and other statements that are not historical facts are forward-looking statements about the future performance of Astellas. These statements are based on management's current assumptions and beliefs in light of the information currently available to it and involve known and unknown risks and uncertainties. A number of factors could cause actual results to differ materially from those discussed in the forward-looking statements. Such factors include, but are not limited to: (i) changes in general economic conditions and in laws and regulations, relating to pharmaceutical markets, (ii) currency exchange rate fluctuations, (iii) delays in new product launches, (iv) the inability of Astellas to market existing and new products effectively, (v) the inability of Astellas to continue to effectively research and develop products accepted by customers in highly competitive markets, and (vi) infringements of Astellas' intellectual property rights by third parties. Information about pharmaceutical products (including products currently in development) which is included in this press release is not intended to constitute an advertisement or medical advice.

###

---

**Contacts for inquiries or additional information:**

Astellas Pharma Inc.  
Corporate Communications  
TEL: +81-3-3244-3201 FAX: +81-3-5201-7473